SEATTLE — Among bariatric surgery patients treated with denosumab to counter bone loss, follow-up treatment with zoledronic acid prevented the rebound effect on markers of bone turnover that is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback